Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2015 / Mar / Google’s Nanoparticular Ambition
Point of care testing Digital and computational pathology Technology and innovation Research and Innovations

Google’s Nanoparticular Ambition

By Roisin McGuigan 03/30/2015 1 min read

Share

Tech firm’s latest project aims to detect disease using a nanoparticle pill and a wrist-worn device

The Google[x] life sciences division is innovating again. This time with nanoparticles. No less ambitious than other projects preceding it (such as its plan to build the largest and most detailed human genome database: Click Here), the tech giant’s latest undertaking aims to create nanoparticles capable of reporting signs of cancer and other diseases using a wearable, magnetic device.

0315-207-main

Speaking at the Wall Street Journal Global Technology Conference (1), project leader, Andrew Conrad, said “Essentially, the idea is simple: You swallow a pill with nanoparticles, and they’re decorated with antibodies, or molecules that detect other molecules. They course through your body and because the core of these particles are magnetic, you can call them somewhere. These little particles go and mingle with the people, we call them back to one place, and we ask them, ‘Hey, what did you see?’” This is certainly an oversimplified way of explaining it, and although magnetic nanoparticle diagnostics are not a new concept, making it work is far from simple. According to Conrad, a wearable sensor containing a magnet would be used to attract and analyze the particles. As well as detecting cancer, it’s hoped the system could be used to spot other disease signs, such as fatty plaque in blood vessels and high potassium levels – potentially creating opportunities for clinicians and pathologists to monitor patients and spot disease before symptoms develop.

That’s certainly ambitious; with many technological and regulatory challenges to overcome, industry experts give the project at least five years before they expect any meaningful results. There is a social factor to consider too: Google’s detractors already point to many of their data collection practices as an invasion of privacy, and there could also be concern over how Google might collect and use private medical data. Despite possible privacy concerns, a system that continually monitors for signs of disease could provide a wealth of information for healthcare providers. According to Conrad, the system is part of a paradigm shift that would see medicine become much more proactive. “Every test you ever go to the doctor for will be done through this system,” he said, “that is our dream.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. The Wall Street Journal, “Google’s newest search: cancer cells”, (2014). Available at: http://on.wsj.com/1sO7sQv. Accessed 9 March 2015.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

What’s New in Infectious Disease? (December 2021)
Point of care testing
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Resisting Resistance
Point of care testing
Resisting Resistance

October 21, 2016

1 min read

Rapid, affordable tests to spot bacterial infections could reduce antibiotic overprescription in resource-limited settings

HIV/AIDS: A Shifting Epidemic
Point of care testing
HIV/AIDS: A Shifting Epidemic

April 4, 2022

1 min read

HIV diagnoses in heterosexual people in the UK have overtaken those in gay and bisexual men

Career Snapshots with Bamidele Farinre
Point of care testing
Career Snapshots with Bamidele Farinre

April 20, 2022

3 min read

Michael Schubert interviews Bamidele Farinre about her work in mobile laboratory testing

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.